Hims and Hers Health Inc vs Roundhill Magnificent Seven ETF — how do they compare? Hims and Hers Health Inc trades at $29.5 (market cap $7.12B), while Roundhill Magnificent Seven ETF trades at $67.63. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals.
| HIMS | MAGS | |
|---|---|---|
Market Cap | $7.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.76 | $70.94 |
52-Week Low | $14.52 | $55.39 |
Enterprise Value | $7.82B | — |
Signals from Pluang's Aura AI — not financial advice
HIMS stock declined 7.11% to $29.51 following mixed Q2 2026 results, where revenue beat expectations but the company posted a wider-than-expected loss. The technical picture is neutral with bearish moving average signals, while fundamentals show strong revenue growth but deteriorating margins. Recent news highlights margin pressure from GLP-1 drug investments and an FTC investigation, creating investor uncertainty despite raised revenue guidance.
The outlook remains cautious as strong subscriber growth and AI initiatives are offset by profitability challenges and regulatory scrutiny. Investment opportunity exists in the company's expanding global footprint and raised revenue targets, but risks include margin compression, negative cash flow trends, and ongoing legal investigations that could pressure the stock near-term.
MAGS trades at $67.95, down 1.58% today, with technical indicators showing a bullish moving average trend but overbought RSI levels. The ETF holds equal-weighted exposure to the Magnificent Seven tech stocks, which have underperformed the broader market this year amid shifting investor focus toward semiconductors and AI infrastructure. Recent news highlights concerns over aggressive AI capital spending pressuring dividends and buybacks.
The outlook remains cautious as AI profit realization lags expectations, though hyperscaler valuations are compressed. Key risks include concentration in tech, high expectations, and macroeconomic sensitivity. Analyst sentiment is mixed, with some seeing long-term AI potential but near-term headwinds from earnings pressure and market rotation.
Trailing returns across standard periods
Latest headlines on both assets
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →